New Indications

The remarkable success of VNS Therapy in the treatment of epilepsy has served as a platform for continued innovation. On July 15, 2005, after seven years of extensive study and clinical trials, VNS Therapy was approved by the FDA as a long-term adjunctive treatment for treatment-resistant depression.

INTENDED USE / INDICATIONS – UNITED STATES

The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over twelve years of age with partial onset seizures which are refractory to antiepileptic medications

The VNS Therapy System is indicated for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.

Please visit www.vnstherapy.com/depression for more information regarding adjunctive VNS Therapy for chronic or recurrent depression.